Insider Transactions in Q1 2024 at Oncternal Therapeutics, Inc. (ONCT)
Insider Transaction List (Q1 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 28
2024
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
6,914
+50.0%
|
$55,312
$8.48 P/Share
|
Feb 23
2024
|
Robert James Wills |
SELL
Open market or private sale
|
Direct |
980
-100.0%
|
$8,820
$9.04 P/Share
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Indirect |
266
+0.89%
|
$2,394
$9.04 P/Share
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Direct |
714
+50.0%
|
$6,426
$9.04 P/Share
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,485
-22.53%
|
$0
$0.5 P/Share
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,955
-10.32%
|
$0
$0.5 P/Share
|
Jan 03
2024
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-12.26%
|
$0
$0.5 P/Share
|
Jan 03
2024
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,868
-5.92%
|
$0
$0.5 P/Share
|
Jan 03
2024
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,742
-13.31%
|
$0
$0.5 P/Share
|
Jan 03
2024
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-21.19%
|
$0
$0.5 P/Share
|